CA3014906C - DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT (MCI), PREDICTION OF THE ONSET OF ALZHEIMER'S DISEASE (AD), AND SCREENING AND MONITORING OF AGENTS FOR THE TREATMENT OF MCI OR THE PREVENTION OF THE ONSET OF DEMENTIA - Google Patents

DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT (MCI), PREDICTION OF THE ONSET OF ALZHEIMER'S DISEASE (AD), AND SCREENING AND MONITORING OF AGENTS FOR THE TREATMENT OF MCI OR THE PREVENTION OF THE ONSET OF DEMENTIA

Info

Publication number
CA3014906C
CA3014906C CA3014906A CA3014906A CA3014906C CA 3014906 C CA3014906 C CA 3014906C CA 3014906 A CA3014906 A CA 3014906A CA 3014906 A CA3014906 A CA 3014906A CA 3014906 C CA3014906 C CA 3014906C
Authority
CA
Canada
Prior art keywords
cells
mci
biomarker
output signal
dementia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3014906A
Other languages
English (en)
French (fr)
Other versions
CA3014906A1 (en
Inventor
Florin V. Chirila
Daniel L. Alkon
Original Assignee
West Virginia University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by West Virginia University filed Critical West Virginia University
Publication of CA3014906A1 publication Critical patent/CA3014906A1/en
Application granted granted Critical
Publication of CA3014906C publication Critical patent/CA3014906C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Primary Health Care (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Physiology (AREA)
  • Evolutionary Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3014906A 2016-02-22 2017-02-22 DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT (MCI), PREDICTION OF THE ONSET OF ALZHEIMER'S DISEASE (AD), AND SCREENING AND MONITORING OF AGENTS FOR THE TREATMENT OF MCI OR THE PREVENTION OF THE ONSET OF DEMENTIA Active CA3014906C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662298182P 2016-02-22 2016-02-22
US62/298,182 2016-02-22
PCT/US2017/018810 WO2017147114A1 (en) 2016-02-22 2017-02-22 Diagnosing mild cognitive impairment (mci), predicting alzheimer's disease (ad) dementia onset, and screening and monitoring agents for treating mci or preventing dementia onset

Publications (2)

Publication Number Publication Date
CA3014906A1 CA3014906A1 (en) 2017-08-31
CA3014906C true CA3014906C (en) 2025-02-18

Family

ID=58361076

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3014906A Active CA3014906C (en) 2016-02-22 2017-02-22 DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT (MCI), PREDICTION OF THE ONSET OF ALZHEIMER'S DISEASE (AD), AND SCREENING AND MONITORING OF AGENTS FOR THE TREATMENT OF MCI OR THE PREVENTION OF THE ONSET OF DEMENTIA

Country Status (5)

Country Link
US (2) US20190041404A1 (https=)
EP (1) EP3420363A1 (https=)
JP (2) JP7134874B2 (https=)
CA (1) CA3014906C (https=)
WO (1) WO2017147114A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3600027B1 (en) 2017-03-31 2026-02-18 Neurodiagnostics LLC Lymphocyte-based morphometric test for alzheimer's disease
US11621087B2 (en) * 2019-09-24 2023-04-04 International Business Machines Corporation Machine learning for amyloid and tau pathology prediction
CN111091906B (zh) * 2019-10-31 2023-06-20 中电药明数据科技(成都)有限公司 一种基于真实世界数据的辅助医疗诊断方法及系统

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595167B2 (en) 2005-10-11 2009-09-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio
US20090029873A1 (en) 2005-10-11 2009-01-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb)
EP2483695A2 (en) * 2009-10-02 2012-08-08 Blanchette Rockefeller Neurosciences, Institute Abnormal alterations of pkc isozymes processing in alzheimer's disease peripheral cells
EP2483684B1 (en) 2009-10-02 2018-04-18 Blanchette Rockefeller Neurosciences, Institute Fibroblast growth patterns to diagnose alzheimer's disease
US20140038186A1 (en) 2010-02-22 2014-02-06 Tapan Kumar Khan Alzheimer's disease-specific alterations of protein kinase c epsilon (pkc-epsilon) protein levels
US20120141498A1 (en) * 2010-12-02 2012-06-07 United States Government As Represented By The Department Of Veterans Affairs Use of pkc isozymes for diagnosis and treatment of neuroblastoma
CA2855932A1 (en) 2011-11-13 2013-05-16 Blanchette Rockefeller Neurosciences Institute Pkc activators and combinations thereof
US20170023552A1 (en) 2014-01-03 2017-01-26 Blanchette Rockefeller Neurosciences Institute Convergence of aggregation rate with validated peripheral diagnostic for alzheimer's disease

Also Published As

Publication number Publication date
JP2019509500A (ja) 2019-04-04
JP7279110B2 (ja) 2023-05-22
JP2021156891A (ja) 2021-10-07
EP3420363A1 (en) 2019-01-02
WO2017147114A1 (en) 2017-08-31
CA3014906A1 (en) 2017-08-31
JP7134874B2 (ja) 2022-09-12
US20240353429A1 (en) 2024-10-24
US20190041404A1 (en) 2019-02-07
US12601750B2 (en) 2026-04-14

Similar Documents

Publication Publication Date Title
US12601750B2 (en) Diagnosing mild cognitive impairment (MCI), predicting alzheimer's disease (AD) dementia onset, and screening and monitoring agents for treating mci or preventing dementia onset
Davies et al. Consensus report of the Working Group on:" Molecular and Biochemical Markers of Alzheimer's Disease"
Baka et al. Studying serum neurofilament light chain levels as a potential new biomarker for small fiber neuropathy
CA2731247A1 (en) Csf biomarkers for the prediction of cognitive decline in alzheimer's disease patients
Hansen et al. Neuropsychological comparison of incident MCI and prevalent MCI
KR20220034769A (ko) 임상적으로 진단된 알츠하이머병 피험자의 혈액 샘플을 사용한 알츠하이머병 바이오마커
US11668721B2 (en) Methods for diagnosing and treating bicuspid aortic valve and/or aortopathies
Restuccia et al. Serum and cerebrospinal fluid biomarkers as predictors of cognitive impairment in multiple sclerosis: a systematic review of longitudinal studies
US20250147050A1 (en) In vitro method for the diagnosis and/or prognosis of multiple sclerosis
Ronald et al. Consensus report of the working group on:“Molecular and biochemical markers of Alzheimer’s disease”
Cousins et al. Electronic health records to test multimorbidity influences to plasma biomarker interpretation for Alzheimer's disease
AbdElghaffar et al. SERUM PHOSPHORYLATED NEUROFILAMENT-HEAVY CHAIN LEVELS IN MULTIPLE SCLEROSIS PATIENTS
RU2808675C1 (ru) Способ дифференциальной диагностики у детей диагнозов детского аутизма легкой степени тяжести течения, атипичного аутизма и шизофрении
WO2024213092A1 (en) Protein markers for mild cognitive impairment and alzheimer's disease
WO2024075803A1 (ja) 脳神経疾患の検査、治療もしくは予防のための方法
Kazakova et al. YKL-40 and Cellular Metabolic Profile in Parkinson’s Disease
WO2024235880A1 (en) Method for diagnosing neurodegenerative diseases
Chen et al. Plasma neurofilament light chain: A novel biomarker of neuroaxonal injury associated with depressive symptoms in epilepsy
Cooper Plasma biomarkers of neurodegeneration across the spectrum of brain health
DuBois et al. Dementia etiology classification using NULISA plasma biomarkers and machine learning
Nejad et al. Assessing the Relationship of CRP and ESR Inflammatory Biomarkers with Acute Multiple Sclerosis Attack and Clinical Syndrome Type in Patients Attending Selected Tehran Hospitals
JP2024054886A (ja) 脳神経疾患の検査、治療もしくは予防のための方法
WO2024133443A1 (fr) Détermination du statut d'un individu vis-à-vis de la maladie d'alzheimer
Goghari S11. BRAIN ABNORMALITIES ASSOCIATED WITH DISEASE-SPECIFIC AND GENETIC RISK FACTORS FOR SCHIZOPHRENIA
Holmes et al. P2-251 Association between dementia and systemic infectious disease: Evidence from a case-control study

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210202

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20250117

Q17 Modified document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED

Effective date: 20250213

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE

Effective date: 20250218

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250219

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250219